The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells

Blood

Volumn 97, Issue 9, 2001, Pages 2604-2610

  Lewis, John L ^a,b   Chinswangwatanakul, Wimol ^a,b   Zheng, Bo ^a,b   Marley, Stephen B ^a,b   Nguyen, Dao X ^a,b   Cross, Nicholas C P ^a,b   Banerji, Lolita ^a,b   Glassford, Janet ^a,b   Thomas, N Shaun B ^a,b   Goldman, John M ^a,b   Lam, Eric W F ^a,b   Gordon, Myrtle Y ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; GROWTH FACTOR; PROTEIN P16;

ANIMAL CELL; ARTICLE; CELL GROWTH; COLONY FORMATION; COLONY FORMING CELL; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; KINETICS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS;

EID: 0035353201     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2604     Document Type: Article

References (47)

1. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67-108.
2. Nakamura K, Koda T, Kakinuma M, et al. Cell cycle dependent gene expressions and activities of protein phosphatases PP1 and PP2A in mouse NIH3T3 fibroblasts. Biochem Biophys Res Comm. 1992;187:507-514.
3. INK4b in human leukemias and lymphomas. Cancer Res. 1995;55:1436-1440.
4. Quesnel B., Preudhomme C, Philippe N, et al. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood. 1995;85:657-663.
5. Sill H, Aguiar CT, Schmidt H, Hochhaus A, Goldman JM, Cross NCR Mutational analysis of the p15 and p16 genes in acute leukaemias. Br J Haematol. 1996;92:681-683.
6. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 1995;86:841-854.
7. Nakamaki T, Kawamata N, Schwaller J, et al. Structural integrity of the cyclin-dependent kinase inhibitor genes p15, p16 and p18 in myeloid leukaemias. Br J Haematol. 1995;91:139-149.
8. inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation. Br J Haematol. 1996;95:291-298.
9. Urashima M, DeCaprio JA, Chauhan D, et al. p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. Blood. 1997;90:4106-4115.
10. Gordon MY, Blackett NM. Some factors determining the minimum number of cells required for successful clinical engraftment. Bone Marrow Transplant. 1995;15:659-662.
11. Gordon MY, Blackett NM. Reconstruction of the hematopoietic system after stem cell transplantation. Cell Transplant. 1998;7:339-344.
12. Gordon MY, Goldman JM. Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br J Haematol. 1996;95:10-20.
13. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
14. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
15. Lam EW-F, La Thangue NB, DP and E2F proteins: coordinating transcription with cell cycle progression. Curr Opin Cell Biol. 1994;6:859-866.
16. Sardet, LeCam LE, Fabbrizio E, Vidal M. Oncogenes as transcriptional regulators. In: Ghysdael J, Yaniv M, eds. Oncogenes as Transcriptional Regulators, Vol 2. Berlin, Germany: Birkhauser Verlag; 1997:1-63.
17. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12:2245-2262.
18. Pegoraro L, Matera L, Ritz J. Establishment of a Ph1-positive cell line, BV173. J Natl Cancer Inst. 1983;70:447-452.
19. Klein E, Ben-Bassat H, Neumann H, et al. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer. 1976;18:421-431.
20. Chinswangwatanakul W. Role of p16 in chronic myeloid leukaemia and normal haemopoiesis [dissertation]. University of London, United Kingdom; 1999.
21. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27-37.
22. He J, Allen JR, Collins VP, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994;54:5804-5807.
23. R gene. Exp Hematol. 1998;26:185-187.
24. Lewis JL, Blackett NM, Gordon MY. The kinetics of colony formation by CFU-GM in vitro. Br J Haematol. 1994;88:440-442.
25. Altman D. Practical statistics for medical research. Oxford, UK, Blackwell Scientific Publications; 1990:433.
26. Gordon MY, Marley SB, Lewis JL, et al. Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest. 1998;102:710-715.
27. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 1995;375:506-510.
28. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell cycle inhibition by the tumor suppressor p16. Nature. 1995;375:503-506.
29. Medena RH, Herrera RE, Lam F, Weinberg RA. Growth suppression by p16 requires functional retinoblastoma protein. Proc Natl Acad Sci U S A. 1995;92:6289-6293.
30. INK4. Science. 1995;267:249-252.
31. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
32. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
33. Li Y, Slansky JE, Myers DJ, Drinkwater NR, Kaetin WG, Farnham PJ. Cloning, chromosomal location, and characterization of mouse E2F1. Mol Cell Biol. 1994;14:1861-1869.
34. Johnson DG. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene. 1995;11:1685-1692.
35. Hu L, Xie E, Chang LS. Different roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins. Mol Cell Biol. 1995;15:3552-3562.
36. Dong F, Cress WD Jr, Agrawal D, Pledger WJ. The role of cyclin D3-dependent kinase in the phosphorylation of p130 in mouse BALB/c 3T3 fibroblasts. J Biol Chem. 1998;273:6190-6195.
37. + progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells. Br J Haematol. 1999;106:644-651.
38. Della Ragione F, Borriello A, Mastropietro S, et al. Expression of G1-phase cell cycle genes during hematopoietic lineage. Biochem Biophys Res Comm. 1997;231:73-76.
39. INK4b in normal human hematopoiesis. Exp Hematol. 1998;26:1133-1139.
40. Quelle D, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993-1000.
41. ink4a/MTS1 gene transcript expressed in B-cell malignancies. Oncogene. 1995;11:21-29.
42. ink4a locus. Cancer Res. 1995;55:2988-2994.
43. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001-5014.
44. Serrano M. The tumor suppresor gene p16INK4a. Exp Cell Res. 1997;237:7-13.
45. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARFINK4a locus delection impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92:725-734.
46. Arf interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92:713-723.
47. Carnero A, Hudson JD, Price CM, Beach DH. P16INK4a and p19Arf act in overlapping pathways in cellular immortalization. Nat Cell Biol. 2000;2:148-155.